Danaher Corporation Stock Price, News & Analysis

Danaher Corporation (NYSE: DHR) has scheduled a webcast for its fourth quarter 2022 earnings conference call on January 24, 2023, at 8:00 a.m. ET. The duration is expected to be around one hour, during which the company will discuss its financial performance and future expectations. Presentations will be available on their website, and a replay will be accessible shortly after the call. Investors can join by dialing in, and additional details will be provided in the Investors section of Danaher’s website.

Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.25 per share for common stock, payable on January 27, 2023, to holders of record on December 30, 2022. Additionally, a cash dividend of $12.50 per share on its 5.00% Series B Mandatory Convertible Preferred Stock will be paid on January 15, 2023, to those on record as of December 31, 2022. This dividend announcement underscores Danaher's commitment to returning value to shareholders.

Danaher Corporation (NYSE: DHR) has announced that its President and CEO, Rainer M. Blair, will present at the Evercore ISI HealthCONx Conference on November 30, 2022, at 10:30 a.m. ET. The presentation will be available via a live webcast on their official website, www.danaher.com.

As a leader in science and technology, Danaher aims to resolve complex challenges while enhancing global quality of life through its innovative solutions.

Cepheid has launched the Xpert Xpress MVP, an FDA-cleared multiplex PCR test that identifies DNA from organisms responsible for bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis from a single sample within an hour. This innovation addresses the 10 million annual healthcare visits related to vaginitis in the U.S., enabling more accurate diagnoses and effective treatments while reducing treatment failures and antimicrobial resistance. The test expedites diagnosis, ultimately enhancing patient outcomes in women's health.

Danaher Corporation (NYSE: DHR) has announced a strategic partnership with Duke University to create the first Danaher Beacon for Gene Therapy Innovation. This initiative aims to leverage breakthrough science for advancements in genomic medicines, precision diagnostics, and biomanufacturing. Dr. Aravind Asokan from Duke will lead the project, focusing on improving viral vector manufacturing. The collaboration, which commenced in late October 2022, is set to extend over several years, emphasizing the importance of academic partnerships in driving innovation in gene therapy.

Danaher Corporation (NYSE: DHR) reported strong Q3 2022 results with net earnings of $1.6 billion, or $2.10 per diluted share, marking a 36% increase year-over-year. Revenues rose 6% to $7.7 billion, while non-GAAP adjusted diluted earnings per share increased 7% to $2.56. The company saw a solid 10% growth in non-GAAP core revenues. Operating cash flow was $2 billion, and free cash flow reached $1.7 billion. Looking ahead, Danaher expects high-single digit growth in non-GAAP core revenue for Q4 and the full year 2022.

Danaher Corporation (NYSE: DHR) has scheduled its third quarter 2022 earnings conference call for October 20, 2022, at 8:00 a.m. ET. This one-hour call will be accessible via webcast on Danaher's website under the Investors section. A slide presentation will accompany the call, and a replay will be available until November 3, 2022. The earnings press release and related materials will be posted at 6:00 a.m. ET on the same day.

Danaher Corporation (NYSE: DHR) announced on September 14, 2022, that its President and CEO, Rainer M. Blair, will discuss the anticipated strong performance of the company in the third quarter 2022 during an investor meeting. The company expects core revenue growth to exceed previous guidance due to increased Cepheid respiratory testing revenue, projected to surpass $500 million compared to the earlier estimate of $325 million. Base business core revenue growth is expected in the high single-digit range.